These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32319599)

  • 1. Gli2 mediates the development of castration‑resistant prostate cancer.
    Xia L; Bouamar H; Gu X; Zeballos C; Qin T; Wang B; Zhou Y; Wang Y; Yang J; Zhu H; Zhang W; Houghton PJ; Sun LZ
    Int J Oncol; 2020 Jul; 57(1):100-112. PubMed ID: 32319599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
    Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X
    Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCAR4 activates GLI2 signaling in prostate cancer to contribute to castration resistance.
    Cai Z; Wu Y; Li Y; Ren J; Wang L
    Aging (Albany NY); 2018 Dec; 10(12):3702-3712. PubMed ID: 30513511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer.
    Liu J; Zhang Y; Li S; Sun F; Wang G; Wei D; Yang T; Gu S
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34738630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer.
    Zhang H; Hu L; Cheng M; Wang Q; Hu X; Chen Q
    Oncol Rep; 2020 Dec; 44(6):2610-2620. PubMed ID: 33125122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.
    Hoang DT; Gu L; Liao Z; Shen F; Talati PG; Koptyra M; Tan SH; Ellsworth E; Gupta S; Montie H; Dagvadorj A; Savolainen S; Leiby B; Mirtti T; Merry DE; Nevalainen MT
    Mol Cancer Ther; 2015 Mar; 14(3):713-26. PubMed ID: 25552366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
    Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S
    Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLI2 promotes cell proliferation and migration through transcriptional activation of ARHGEF16 in human glioma cells.
    Huang D; Wang Y; Xu L; Chen L; Cheng M; Shi W; Xiong H; Zalli D; Luo S
    J Exp Clin Cancer Res; 2018 Oct; 37(1):247. PubMed ID: 30305138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
    Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gli as a novel therapeutic target in malignant pleural mesothelioma.
    Li H; Lui N; Cheng T; Tseng HH; Yue D; Giroux-Leprieur E; Do HT; Sheng Q; Jin JQ; Luh TW; Jablons DM; He B
    PLoS One; 2013; 8(3):e57346. PubMed ID: 23483902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.
    Lopez SM; Agoulnik AI; Zhang M; Peterson LE; Suarez E; Gandarillas GA; Frolov A; Li R; Rajapakshe K; Coarfa C; Ittmann MM; Weigel NL; Agoulnik IU
    Clin Cancer Res; 2016 Aug; 22(15):3937-49. PubMed ID: 26968201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.
    Chen M; Feuerstein MA; Levina E; Baghel PS; Carkner RD; Tanner MJ; Shtutman M; Vacherot F; Terry S; de la Taille A; Buttyan R
    Mol Cancer; 2010 Apr; 9():89. PubMed ID: 20420697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of GLI2 with antisense-oligonucleotides: A potential therapy for the treatment of bladder cancer.
    Raven PA; Lysakowski S; Tan Z; D'Costa NM; Moskalev I; Frees S; Struss W; Matsui Y; Narita S; Buttyan R; Chavez-Munoz C; So AI
    J Cell Physiol; 2019 Nov; 234(11):20634-20647. PubMed ID: 31012113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lncRNA PTTG3P promotes the progression of CRPC via upregulating PTTG1.
    Huang S; Liao Q; Li W; Deng G; Jia M; Fang Q; Ji H; Meng M
    Bull Cancer; 2021 Apr; 108(4):359-368. PubMed ID: 33743960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression.
    Jin R; Yamashita H; Yu X; Wang J; Franco OE; Wang Y; Hayward SW; Matusik RJ
    Oncogene; 2015 Jul; 34(28):3700-10. PubMed ID: 25220414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
    Carpenter V; Saleh T; Min Lee S; Murray G; Reed J; Souers A; Faber AC; Harada H; Gewirtz DA
    Biochem Pharmacol; 2021 Nov; 193():114765. PubMed ID: 34536356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT).
    Choi JD; Kim TJ; Jeong BC; Jeon HG; Jeon SS; Kang MY; Yeom SY; Seo SI
    Sci Rep; 2021 Nov; 11(1):21984. PubMed ID: 34753990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells.
    Xu M; Sakamoto S; Matsushima J; Kimura T; Ueda T; Mizokami A; Kanai Y; Ichikawa T
    J Urol; 2016 May; 195(5):1588-1597. PubMed ID: 26682754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.